Regulus, UCSD Partner on miRNA for Angiogenic Diseases | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Regulus Therapeutics today announced it is collaborating with researchers at the University of California, San Diego School of Medicine to develop treatments for angiogenic disease using microRNA therapeutics.

The collaboration combines Regulus' miRNA platform with UCSD's expertise in animal models of angiogenesis. The collaboration recently received a UC Discovery Grant that promotes work between the university's researchers and industry.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.